Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 3/20 | 0.95 |
| ▸ | NSD2 | O96028 | 3/20 | 0.95 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.95 |
| ▸ | ABL1 | P00519 | 1/20 | 0.95 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.95 |
| ▸ | CES1 | P23141 | 1/20 | 0.95 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.95 |
| ▸ | GAA | P10253 | 1/20 | 0.86 |
| ▸ | PTPRC | P08575 | 2/20 | 0.75 |
| ▸ | CTSL | P07711 | 1/20 | 0.75 |
| ▸ | CTSS | P25774 | 1/20 | 0.75 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | S100A4 | P26447 | 6/20 | 0.63 |
| ▸ | CDC25B | P30305 | 3/20 | 0.63 |
| ▸ | PADI1 | Q9ULC6 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27145668 | 1.00 | TDP2 (0.95) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL29419580 | 0.97 | TDP2 (1.00) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL460433 | 0.97 | TDP2 (1.00) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL3275080 | 0.95 | TDP2 (0.95) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL5696693 | 0.95 | TDP2 (0.95) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL579998 | 0.92 | GAA (1.00) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL29551149 | 0.92 | GAA (1.00) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL30774319 | 0.92 | GAA (1.00) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL5915065 | 0.87 | TDP2 (0.81) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL30385090 | 0.87 | TDP2 (0.79) | TDP2NSD2PAX8ABL1PLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050064388-A1 | Methods and compositions for treating atheroma, tumors and other neoplastic tissue | UNIVERSITY OF TEXAS | 2005-03-24 | — | — | US | claimed |
| US-20210238672-A1 | SYSTEMS AND METHODS FOR DETECTION OF BIOMOLECULES | QUANTUM BIOSYSTEMS INC (JP) | 2021-08-05 | — | — | US | disclosed |
| WO-2021125310-A1 | SYSTEMS AND METHODS FOR DETECTION OF BIOMOLECULES | QUANTUM BIOSYSTEMS INC. (JP) | 2021-06-24 | — | — | WO | disclosed |
| US-7579338-B2 | Motexafin gadolinium, acetic acid, and water | PHARMACYCLICS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7547689-B2 | Methods and compositions for treating atheroma, tumors and other neoplastic tissues | PHARMACYCLICS, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20070004699-A1 | METHODS AND COMPOSITIONS FOR TREATING ATHEROMA, TUMORS AND OTHER NEOPLASTIC TISSUES | PHARMACYCLICS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-7109188-B2 | Methods and compositions for treating atheroma, tumors and other neoplastic tissue | PHARMACYCLICS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060178314-A1 | Methods and compositions for treating atheroma, tumors and other neoplastic tissues | UNIVERSITY OF TEXAS | 2006-08-10 | — | — | US | disclosed |
| US-20050064388-A1 | Methods and compositions for treating atheroma, tumors and other neoplastic tissue | UNIVERSITY OF TEXAS | 2005-03-24 | — | — | US | disclosed |
| US-6825186-B1 | METAL CONTAINING TEXAPHYRIN | PHARMACYCLICS, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20030031676-A1 | Conjugate compounds for treating atheroma and other diseases | PHARMACYCLICS, INC. | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004699-A1 | METHODS AND COMPOSITIONS FOR TREATING ATHEROMA, TUMORS AND OTHER NEOPLASTIC TISSUES | GSTK1, NR1H3, NR1H2 | TDP2 2290/4885NSD2 4461/4885PAX8 4182/4885 |
| US-20050064388-A1 | Methods and compositions for treating atheroma, tumors and other neoplastic tissue | NR1H3, GSTK1, NR1H2 | TDP2 2192/4885NSD2 4433/4885PAX8 4213/4885 |
| US-20060178314-A1 | Methods and compositions for treating atheroma, tumors and other neoplastic tissues | CD68, APOB, MEN1 | TDP2 1177/4885NSD2 3677/4885PAX8 2038/4885 |
| US-20030031676-A1 | Conjugate compounds for treating atheroma and other diseases | NQO1, AKR7A2, CYP46A1 | TDP2 2007/4885NSD2 4528/4885PAX8 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.